|Systematic (IUPAC) name|
|methyl [(5-propylsulfanyl-3H- benzoimidazol-2-yl) amino]formate|
|Mol. mass||265.333 g/mol|
|Metabolism||oxidation of sulphur atom to sulphoxide, the active metabolite|
on the counter (OTC)
|Routes||only oral route|
Albendazole, marketed as Albenza, Eskazole or Zentel, is a member of the benzimidazole compounds used as a drug indicated for the treatment of a variety of worm infestations. Although this use is widespread in the United States, the FDA has not approved albendazole for this indication.
It is effective against
Mode of action
Vermicidal: Albendazole (C12H15N3O2S) causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
Albendazole also has been shown to inhibit the enzyme fumarate reductase, which is helminth-specific. This action may be considered secondary to the effect on the microtubules due to the decreased absorption of glucose. This action occurs in the presence of reduced amounts of nicotinamide-adenine dinucleotide in reduced form (NADH), which is a coenzyme involved in many cellular oxidation-reduction reactions.
D (Australia) - Do not take when pregnant, and do not become pregnant for one month after taking this drug.
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies